Moshosho rice controversy: FDA confirms product wholesome

The Food and Drugs Authori­ty (FDA) says it conducted due diligence in extend­ing the Best Before End (BBE) date of Moshosho rice before it was released for distribu­tion.

Consequently, the Authority said it confirmed that the rice, which was distributed to Senior High Schools (SHSs) nationwide and became a matter of public con­cern recently, was wholesome.

“The FDA also wishes to assure the public that it confirmed the wholesomeness of the consignment of the rice in question and gives the assurance that it was wholesome before it was released for distribu­tion, Dr Delese Mimi Darko, the Chief Executive Officer (CEO) of the FDA, noted at a press confer­ence in Accra on Tuesday.

It is recalled that Mr Samuel Okudzeto Ablakwa, the Member of Parliament for North Tongu, alleged that SHS students were fed with expired rice imported from India.

He made a number of ac­cusations about Moshosho rice, including re-bagging and packaging of the product without recourse to FDA regulations.

But, in setting the records straight, the FDA said it did noth­ing untoward.

Dr Darko revealed that on December 4, 2023, Lamens Invest­ments Africa Limited, the company at the centre of the controversy, applied to the FDA for a shelf-life extension of a consignment of Moshosho white Doubled Sortex Indian Rice, referencing that the product met quality specifications.

She said on December 20, 2023, the FDA Kumasi office, received report of repackaging of rice in a NAFCO warehouse.

Dr Darko underlined that the FDA officers, accompanied by personnel of the Ghana Police Service (GPS), Kumasi, inspected the facility, which was previously locked by the police, confirmed the repackaging, and re-sealed the premises.

She said an administrative fine of GH¢100,000 was imposed on the importer, for the repackaging contrary to the provisions of the Public Health Act, 2012 (Act 851).

Additionally, Dr Darko said following the submission of the report on preliminary investigation by the FDA, Kumasi, it was realised that the product in question had BBE date of December 2023, and not an expiry date as contained on the initial situation with analytical  report from the Centre for Scientif­ic and Industrial Research (CSIR).

She further explained that from December 20, 2023, to January 24, 2024, the warehouse remained sealed, with periodic opening for cleaning and ventilation under joint supervision by the FDA and the GPS.

She noted that the manufac­turer of the rice, Satyam Balance Rice Ind Pvt Ltd., India, through Lamens, submitted a letter, dated December 21, 2023, confirming that the product, if properly stored under dry conditions and regularly fumigated, could be consumed within three years; one year exten­sion of the BBE date to December 2024.

Dr Darko indicated that based on that, the FDA did a thorough review of the analytical report from CSIR and the FDA’s own confir­matory analytical report of samples submitted by its Enforcement Directorate (confirmed that the rice was wholesome at the time of the analysis).

BY MALIK SULLEMANA

The post Moshosho rice controversy: FDA confirms product wholesome appeared first on Ghanaian Times.